Dal 7FP a Horizon 2020

Transcript

1 Dal 7FP a Horizon 2020 Info Day Progetto Mattone Internazionale Innovazione sanitaria: quale futura dimensione strategica, passi immediati Sala Convegni Ospedale Ca Foncello, Azienda ULSS 9 Gianluca Quaglio Treviso 10 dicembre 2013

2 Programma Quadro per la Ricerca Principale strumento sovranazionale per il finanziamento della ricerca in Europa PQ 1: 1984 PQ7:

3 FP7: I programmi 1. Cooperation Collaborave research 32 miliardi 2. Ideas Froner Research 8 miliardi 3. People Marie Curie Acons 5 miliardi 4. Capacities Research Capacity 4 miliardi

4 Programma Cooperation, tema salute: finanziamento per Regione Periodo: gennaio 2007 aprile 2011 (in milioni di euro)

5 FP FP7: Horizon 2020:

6 Horizon 2020

7 Budget del FP FP7: 55 M H2020: 70 M FP1: 3 M

8 H2020: cosa c e di nuovo Semplificazione Spinta all innovazione Maggiore approccio bottom-up Forte supporto alle SMEs (15% del budget alle SMEs) Maggiore link con la cohesion policy(fondi strutturali)

9 Semplificazione Un singolo set di regole: uguali per tutti (università & industria) Regole di partenariato piu semplici Meno documenti necessari per la partecipazione Un singolo punto di accesso per i partecipanti Un piu facile sistema di rimborso dei costi sostenuti

10 Semplificazione Meno controlli e meno audits Ex-ante financial capacity check solo per i coordinatori Il numero di ex-post audit sarà ridotto Procedurepiù rapide Ridotto il time to grant da 12 mesi attuali a 8 mesi

11 1. Eccellenza scientifica H2020: tre priorita 2. Leadership industriale 3. Sfide sociali

12 1. Eccellenza scientifica European Research Council (ERC) Future and Emerging Technologies (FETs) Marie Curie Actions Infrastrutture di ricerca

13 2. Leadership industriale La ricerca EU deve saper attrarre maggiori investimenti privati

14 3. Sfide sociali La Cooperation di FP7 Budget TEMI Health, demographic change Food Efficient energy Transport Inclusive societies Climate action

15

16 Generalita Periodo Budget: 1. 2 M Topic meno dettagliati nel contenuto Topic con valutazione in due stages 2 grandi focus area A. Personalisinghealthand care B. Co-ordination activities

17 Budget Call Budget 2014 (milioni ) Budget 2015 (milioni ) Personalising health and care Co-ordination activities Altre

18 Personalising health and care 34 topic 15 apertinel apertinel apertinel2014 e 2015

19 Personalising health and care Aperturacall: 11 dicembre2013 Deadlines 2014: 11 Marzo 2014 (stage 1 delle call a due stage) 15 Aprile 2014 (per call a single stage) 19 Agosto 2014 (stage 2 delle call a due stage)

20 Personalising health and care Topic Stage 1 Stage 2 PHC PHC PHC PHC PHC PHC PHC PHC PHC PHC PHC /2015 PHC PHC PHC PHC PHC Marzo Agosto 2014 Single stage 15 Aprile 2014 PHC /2015 Fase1 Fase2 Fase1 Fase2

21 Personalising health and care Meccanismi delle malattie e dell invecchiamento(1-3) Promozione, prevenzione, screening (4-9) Diagnosi(10-12) Trattamenti innovativi(13-18) Anzianita attiva(19-22) Citizen-centred care (23-29) Health information (30-34)

22 Understanding health, ageing and disease 1 -Determinants, risk factors and pathways 2 -Systems medicine 3 -Understanding common mechanisms of diseases and their relevance in co-morbidities

23 Health promotion, disease prevention and screening 4 -Improved inter-sector co-operation for environment and health based interventions 5 -Translating omics into stratified approaches 6 -Evaluating existing screening and prevention programmes 7 -Improving the control of infectious epidemics and foodborne outbreaks through rapid identification of pathogens 8 -Vaccine development for poverty-related and NIDs: Tuberculosis 9 - Vaccine development for poverty-related and NIDs: HIV/AIDS

24 Improving diagnosis 10 -Development of new diagnostic tools and technologies: in vitro devices, assays and platforms 11 -Development of new diagnostic tools and technologies: in vivo medical imaging technologies 12 -Clinical validation of biomarkers and/or diagnostic medical devices

25 Innovative treatments and technologies 13 -New therapies for chronic non-communicable diseases 14 -New therapies for rare diseases 15 - Clinical research on regenerative medicine 16 - Tools and technologies for advanced therapies 17 -Comparing the effectiveness of existing healthcare interventions in the elderly 18 -Establishing effectiveness of health care interventions in the paediatric population

26 Advancing active and healthy ageing 19 -Advancing active and healthy ageing with ICT: Service robotics within assisted living environments; and ICT solutions for independent living with cognitive impairment 20 -Advancing active and healthy ageing with ICT: ICT solutions for independent living with cognitive impairment 21 -Advancing active and healthy ageing with ICT: Early risk detection and intervention 22 -Promoting mental wellbeing: in the ageing population

27 Integrated, sustainable, citizen-centred care 23 -New models for safe and efficient, prevention oriented, health and care systems 24 -Piloting personalised medicine in health and care systems 25 -Advanced ICT systems and services for Integrated Care 26 -Self-management of health and disease: citizen engagement and mhealth 27 Self-management of health and disease: patient empowerment supported by ICT 28 -Self-management of health and disease: decision support systems based on predictive computer modelling used by the patient 29 - Public procurement of innovative ehealth services

28 Improving health information, data exploitation and providing an evidence base for health policies and regulation 30 -Digital representation of health data to improve diseases' diagnosis and treatment 31 - Foresight for health policy development and regulation 32 -Advancing bioinformatics to meet biomedical and clinical needs 33 - New approaches to improve predictive human safety testing 34 -ehealthinteroperability

29

30 2.1.1: Diet, impulsivity and compulsivity Scope: The activities shall deliver new insights into the influence of diet (the sugar metabolism, fat and protein content, vitamin and mineral balance) in various population groups (including children teenagers and the elderly)

31 2.2.1: Tackling malnutrition in the elderly population Scope: Strategies to prevent malnutrition in the elderly (at home, in ambient assisted living, in nursing homes, in hospitals, and/or in an emergency context) will be developed.

32 Health for Growth Programme Caratteristiche generali Durata: Budget: 450 milioni euro

33 Health for Growth Programme Caratteristiche generali Community action programme in the field of health EUR 312 million 2 nd Community action programme in the field of health EUR 321,5 million 3 rd Union action programme in the field of health EUR 446 million

34 Health for Growth Programme Obiettivo n. 1 Promuovere la salute, la prevenzione delle malattie e la creazione di ambienti di vita salubri Prevenzione: alcool, tabacco, dieta, etc Prevenzione di patologie croniche Prevenzione, diagnosie curadi malattieinfettive: HIV, TB, epatite Informazione sulla salute

35 Health for Growth Programme Obiettivo n. 2 Sviluppare soluzioni condivise (cross border solutions), capacity building e linee guida comuni

36 Health for Growth Programme Obiettivo n. 3 Innovare i sistemi sanitari, per renderli efficienti e sostenibili HTC E-health solutions Health in ageing society Etc.

37 Health for Growth Programme Obiettivo n. 4 Facilitare l accesso a migliori e piu sicuri sistemi di cura

38 IMI: esempio di Joint Technology Initiatives Budget: 2 billion Euro (1 da EC, 1 da EFPIA) La piu grande public private partnership in life sciences del mondo La EC finanzia solo la partecipazione di public organisations, università e SMEs. Le industrie farmaceutiche finanziano la propria partecipazione in kind: staff, laboratori, consumabili, etc

39 Come prepararsi a H2020? Chi sono i key player? Costruire link ora! ERC: sviluppare già delle idee Contatti a Bxl Chi sono i gruppi leader in precedenti progetti? Come fareper incontrarli? Funzionari della CE Venetia Bxl Meeting, conferenze Iscriversial database degli esperti EU

40 Public Funding for Research (Source : ERA Key Figures 2005, EC) Mio Euro Germany France UK Italy EU Commission Spain Netherlands Sweden Austria Belgium Denmark Finland Poland Portugal Greece Czech rep. Ireland Hungary Slovenia Romania Slovakia Bulgaria Lithuania Estonia Malta Luxembourg Cyprus Latvia China Japan United States Restructuring a fragmented ERA

41 Public Funding for Research (Source : ERA Key Figures 2005, EC) Mio Euro Germany France UK Italy EU Commission Spain Netherlands Sweden Austria Belgium Denmark Finland Poland Portugal Greece Czech rep. Ireland Hungary Slovenia Romania Slovakia Bulgaria Lithuania Estonia Malta Luxembourg Cyprus Latvia China Japan United States Restructuring a fragmented ERA EU27 + EC

42 Diversi strumenti per la ricerca in salute in EU PQ Altri JTI Ricerca europea Coordinaz. SM FS IET